绥美凯（多替阿巴拉米片）适应症

What are the indications for Suimeikai (Domitabalamid Tablets, Inbec)? Let’s find out together below. Suimeikai (dolute abalamib tablets, Inbec) has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Suimeike (Dolutea Paramid Tablets, Inbec) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Trimax (dolutegravir, Inbec) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine can be used. In these cases, physicians should refer to the respective product information for these medicines.

HIV is a virus that attacks the body's immune system. It takes the most important CD4 T lymphocytes in the human immune system as its main attack target, destroys these cells in large quantities, and causes the human body to lose its immune function. Therefore, the human body is susceptible to various diseases, and malignant tumors can occur, with a high mortality rate. The average incubation period of HIV in the human body is 8 to 9 years. In 2018, GSK announced the launch of integrase DTG (Inbec) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. Inbec (Inbec) uses DTG, an integrase inhibitor, as the core drug, and is combined with abacavir and lamivudine as a treatment plan. It is made into a single-tablet treatment and promoted, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

The above are the indications of Suimeikai (Domitabalamid Tablets, Inbec) provided by our Medical Companion Overseas Medical Consulting Service Company.